Replies to post #230665 on Biotech Values

[zipjet]

>>whether to remain on an ACE/ARB during the COVID-19 pandemic is a tough call...

Considering the data so far, I will continue to take my ARB.


ij

[biocqr]

3.7% mortality in ACE/ARB group vs 9.8% in non-ACE/ARB group in China trial...

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.317134

Methods and Results: This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [IQR 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [IQR 57-69]; 53.5% men), who were admitted to nine hospitals in Hubei Province, China from December 31, 2019 to February 20, 2020. Unadjusted mortality rate was lower in the ACEI/ARB group versus the non-ACEI/ARB group (3.7% vs. 9.8%; P = 0.01).